Desensitisation With Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
Status:
Not yet recruiting
Trial end date:
2029-09-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about the efficacy and safety of imlifidase in
highly sensitized paediatric patients, 1-17 years old, with end stage renal disease (ESRD).
The main questions it aims to answer are:
- Does imlifidase treatment result in crossmatch conversion that enables transplantation?
- How is the function of the transplanted kidney?
The participants will be hospitalised in accordance with the normal routines for transplanted
patients. The patients will receive medication to prevent rejection of the donor kidney, and
because such treatment make the body more vulnerable medications to prevent infections.